Evoke Pharma, Inc. (EVOK): Price and Financial Metrics

Evoke Pharma, Inc. (EVOK): $0.53

0.06 (+11.93%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add EVOK to Watchlist
Sign Up

EVOK Price/Volume Stats

Current price $0.53 52-week high $1.77
Prev. close $0.47 52-week low $0.40
Day low $0.48 Volume 113,400
Day high $0.60 Avg. volume 46,917
50-day MA $0.49 Dividend yield N/A
200-day MA $0.86 Market Cap 4.54M

EVOK Stock Price Chart Interactive Chart >


Evoke Pharma, Inc. (EVOK) Company Bio


Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.


EVOK Latest News Stream


Event/Time News Detail
Loading, please wait...

EVOK Latest Social Stream


Loading social stream, please wait...

View Full EVOK Social Stream

Latest EVOK News From Around the Web

Below are the latest news stories about EVOKE PHARMA INC that investors may wish to consider to help them evaluate EVOK as an investment opportunity.

Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray

Evoke Pharma CEO Dave Gonyer joined Steve Darling from Proactive to share news the company has achieved a significant milestone with the listing of its recently issued U.S. patent related to GIMOTI...

Yahoo | November 30, 2023

Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

GIMOTI now holds four listed patents with coverage through 2029SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its recently issued U.S. patent related to GIMOTI, No. 11,813,231 is now listed in the U.S. Food and Drug Administration (FDA) publication, “Approved Drug Products with Th

Yahoo | November 27, 2023

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

The Company Will Submit for FDA Orange-Book Listing in the Near TermSOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the Company’s com

Yahoo | November 14, 2023

Evoke Pharma Reports Third Quarter 2023 Financial Results

38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDA

Yahoo | November 9, 2023

Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023

Reduction in emergency department visits, hospitalizations and office visits caused diabetic gastroparesis patients and insurers to save over $15,000 for each patient in a six-month period by treating with GIMOTI versus oral metoclopramide Image 1 All-Cause HCRU visits in 6-month post-index period for NMCP and OMCP patients Image 2 All-Cause HRCU Costs between NMCP and OMCP patients over 6-month post index period SOLANA BEACH, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:

Yahoo | October 31, 2023

Read More 'EVOK' Stories Here

EVOK Price Returns

1-mo 13.98%
3-mo -10.62%
6-mo -53.71%
1-year N/A
3-year -96.91%
5-year -92.95%
YTD -49.54%
2023 -60.81%
2022 -59.39%
2021 -78.68%
2020 59.26%
2019 -34.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!